Sun Pharma launches Ilumya® in India for Plaque Psoriasis treatment
Sun Pharma launches Ilumya in India for treating moderate-to-severe plaque psoriasis. Clinical trials showed significant skin clearance and improvements. The drug is available in 35 countries.
The launch of a new drug in a significant market like India is likely to have a medium impact on the company's revenue and market position.
The announcement highlights the launch of a new drug with positive clinical trial results and endorsements from medical professionals, indicating a positive development for the company.
* Sun Pharma has launched its global innovative drug, ILUMYA (Tildrakizumab), in India for the treatment of moderate-to-severe plaque psoriasis. * ILUMYA is a novel biologic treatment widely endorsed by dermatologists in the US and worldwide. * According to Kirti Ganorkar, Managing Director of Sun Pharma, ILUMYA offers a safe and effective treatment option for patients. * ILUMYA is currently available in 35 countries and has demonstrated significant and long-lasting skin clearance. * A clinical study in India involving 115 patients showed significant skin clearance, with 93.9% of patients achieving ≥75% reduction in Psoriasis Area Severity Index Score at Week 28. * Dr. B. S. Chandrashekar highlighted the significant improvements across all measures, with approximately 93.5% reduction in PASI score and pronounced skin clearance in the Phase-3 trial. * ILUMYA is the first IL-23 inhibitor to complete five years of study, demonstrating its potential as a sustainable choice for long-term treatment.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.